Denali Therapeutics (DNLI) Interest Expenses (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Interest Expenses data on file, last reported at $566000.0 in Q1 2026.

• On a quarterly basis, Interest Expenses fell 80.48% year-over-year to $566000.0 in Q1 2026; TTM through Mar 2026 was $566000.0, a 95.09% decrease from a year earlier, with the FY2025 full-year figure at $14.1 million, down 97.11% from the prior year.
• Interest Expenses for Q1 2026 stood at $566000.0, down from $3.0 million in the prior quarter.
• Over the last five years, Interest Expenses for DNLI reached as high as $48.1 million in Q2 2025 and fell as low as $566000.0 in Q1 2026.
• Historically, Interest Expenses has averaged $5.4 million across 5 years, with a median of $2.9 million in 2024.
• Across the five-year window, Interest Expenses surged 1585.63% in 2025 and slumped 80.48% in 2026, its largest moves.
• Year by year, Interest Expenses stood at $3.0 million in 2022, then dropped by 6.78% to $2.8 million in 2023, then rose by 3.29% to $2.9 million in 2024, then climbed by 3.29% to $3.0 million in 2025, then slumped by 81.01% to $566000.0 in 2026.
• Per Business Quant data, the three most recent Interest Expenses figures were $566000.0 in Q1 2026, $3.0 million in Q4 2025, and $3.0 million in Q3 2025.